(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”) (“Helix” or the “Company”), a immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced the completion of the collaboration agreement with ProMab Biotechnologies, Inc. (“ProMab”) to develop novel antibody and chimeric antigen receptor T-cell therapy (“CAR-T”) for particular hematological malignancies (i.e. multiple myeloma).
The Company had previously announced the signing of a binding letter of intent (“LOI”) with ProMab to develop CAR-T for various hematological malignancies and solid tumours. Today the Company announced the signing of the first scientific collaboration to co-develop a cell-based therapy for Multiple Myeloma.